Bruker Corporation (BRKR) is a publicly traded Healthcare sector company. As of July 5, 2026, BRKR trades at $61.64 with a market cap of $9.38B and a P/E ratio of -256.83. BRKR moved +1.67% today. Year to date, BRKR is +29.74%; over the trailing twelve months it is +45.17%. Its 52-week range spans $28.53 to $64.64. Analyst consensus is buy with an average price target of $52.38. Rallies surfaces BRKR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bruker’s BioSpec 18T MRI Boosts Spatial Resolution for Cancer, Neuroscience: Bruker Corp commissioned a BioSpec™ 18 Tesla preclinical MRI at Champalimaud Foundation in Lisbon. The system provides increased spatial resolution and sensitivity for in vivo cancer and neuroscience research, complementing existing 16.4T and 9.4T systems to enable advanced biomarker discovery.
| Metric | Value |
|---|---|
| Price | $61.64 |
| Market Cap | $9.38B |
| P/E Ratio | -256.83 |
| EPS | $-0.24 |
| Dividend Yield | 0.05% |
| 52-Week High | $64.64 |
| 52-Week Low | $28.53 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.46B |
| Net Income | $-9.40M |
| Gross Margin | 45.29% |
9 analysts cover BRKR: 0 strong buy, 4 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $52.38.